Amicus Therapeutics Commences Phase 1 Clinical Trials for AT2220 for Pompe Disease
Cranbury, NJ – December 14, 2006

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has commenced Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, following acceptance of an investigational new drug application (IND) by the U.S. Food and Drug Administration (FDA).

Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a relatively rare lysosomal storage disorder caused by an inherited mutation in the lysosomal enzyme a-glucosidase (GAA). GAA is normally made in the endoplasmic reticulum where it is properly folded and subsequently trafficked to the lysosome where it catalyzes the breakdown of glycogen. In many Pompe patients, a genetic mutation alters the structure and stability of GAA which results in reduced levels of enzyme in the lysosome and reduced cellular activity. The deficiency in GAA activity leads to excessive glycogen accumulation in the cells of various tissues, especially in heart and skeletal muscle.

AT2220 is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of GAA to the lysosome, where it can perform its normal function. AT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA.

“We are very pleased to see continued progress in the fight against Pompe disease,” says Dr. Sharon Hesterlee, Vice President of Translational Research at the Muscular Dystrophy Association (MDA). “We look forward to exploring the opportunities to work with Amicus as this new potential treatment option for individuals and families with Pompe disease is evaluated through human clinical trials.”

“AT2220 for Pompe disease is the third Amicus product to enter clinical trials,” says Donald Hayden, Amicus interim President and CEO. “This accomplishment further demonstrates the company's progress in developing new potential treatments for important diseases using pharmacological chaperone technology.”

The company's lead compound, Amigal™ (migalastat hydrochloride), is in Phase 2 clinical trials for Fabry disease and AT2101 is in Phase 1 clinical trials for the treatment of Gaucher disease.

About Pompe Disease
Pompe disease affects an estimated 5,000-10,000 patients worldwide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. The early onset form of the disease is the most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death from cardio-respiratory failure between 1 and 2 years of age. The late onset form of the disease begins between childhood and adulthood and has a slower rate of progression that is characterized by musculoskeletal and pulmonary symptoms that usually lead to progressive weakness and respiratory insufficiency.

About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded proteins caused by genetic mutations. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus' is currently conducting Phase 2 clinical trials for its lead compound, Amigal™, for Fabry disease, and is conducting Phase 1 clinical trials of AT2101 for Gaucher disease and AT2220 for Pompe disease.

U.S. Congressman Rush Holt Visits VaxInnate to Announce Government Funding for Collaborative Malaria Vaccine Development; Defense Appropriations Act Awards $1million to VaxInnate for Vaccine Research
Cranbury, NJ – November 30, 2006

U.S. Congressman Rush Holt, representing the 12th District of New Jersey, visits VaxInnate Corporation's NJ headquarters today to announce that the company has been awarded $1 million in 2007 federal funds to support collaboration with the U.S. Department of Defense on malaria vaccine research. The appropriation is part of the Defense Appropriations Act of 2007.

VaxInnate is developing novel, proprietary vaccines for infectious diseases based on its Toll-like receptor (TLR) technology platform, which has the potential to substantially improve vaccine immunogenicity and efficacy. The appropriation will be used to support additional pre-clinical research on a malaria vaccine based on the company's TLR platform, as applied to known malarial antigens.

"I am pleased to see the innovative research and development of improved vaccine technologies that is occurring right here in Central New Jersey," said Rep. Holt. "The current egg-based method of vaccine development and production is outdated and unreliable. The groundbreaking R&D occurring in Cranbury holds real promise in improving the health of all Americans."

“This represents another significant milestone for VaxInnate, and we thank Congressman Holt for his tireless efforts to represent the interests of the life sciences sector here in his District,” said Alan Shaw, President and CEO of VaxInnate. “The funding will enable us to collaborate with DoD in demonstrating how our technology platform can dramatically change the way we approach malaria vaccine development – with the potential to not only improve potency but also reduce costs and greatly expand the scale of production to better protect the military, and reach vast underserved populations.”

Almost half of the world's population lives in areas where they are exposed to risk of malaria, and increasing numbers of visitors to endemic areas are also at risk. According to a recent report on the status of DoD's malaria program issued by the Institute of Medicine (Battling Malaria), malaria has persisted as a formidable problem for the U.S. military throughout its history. The report also recommended that DoD should “markedly enhance its research and development efforts to produce malaria vaccines suitable for DoD needs.”

VaxInnate's TLR technology platform works by combining proteins of vaccine antigen and bacterial flagellin, a component of the long hair-like tails that help bacteria swim and an example of a molecular pattern recognized by TLRs. These combined vaccines are extremely immunogenic because they trigger an innate immune response through the flagellin, which in turn stimulates a vigorous adaptive immune response to the antigen. The method produces robust immune responses in animal models to malaria, human and avian influenza, Dengue fever, Japanese encephalitis, and other diseases. In addition, because flagellin is a stable bacterial protein, these products are also simple to make using recombinant DNA techniques.

About VaxInnate
VaxInnate is a privately-held biotechnology company focused on developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's Toll-like receptor (TLR) technology platform allows for genetic engineering of the vaccines using recombinant DNA techniques. This technology physically links TLR agonists to vaccine antigens, which allows the conjugated vaccine to trigger an adaptive immune response. VaxInnate is using its TLR platform technology to enhance the immunogenicity of a series of antigens which will be combined into a number of different influenza products. The technology platform is also being investigated for development of vaccines for other diseases. For more information on VaxInnate, please visit http://www.vaxinnate.com.

Millennium Pharmacy Systems To Supply Advanced Pharmacy Technology For Asbury Communities, the Nation's 9th Largest Non-Profit Senior Care Provider; Leading Long-Term Care Organization Aligns With Technology Innovator to Provide Safe Medication Management
Gaithersburg, PA – November 29, 2006

Asbury Communities, Inc., the nation's ninth largest non-profit long-term care provider, announced it has signed an agreement with Millennium Pharmacy Systems, Inc. (MPSRx), a pioneer in long-term care technology, to use Millennium's MPSRx 360 state-of-the-art pharmacy solution to continuously improve quality related to pharmacy services at Asbury's communities in multiple states.

Developed by Nurses for Nurses, MPSRx 360 utilizes real-time proprietary software, bar coded prescription packaging and handheld bar code scanning devices to enhance resident safety and reduce pharmacy services costs. Asbury's commitment to safety and quality led their management team to seek out the safest technology available to provide even better medication management throughout the organization's skilled nursing, assisted living and independent living settings.

“Our long-standing devotion to exceptional services for senior care drives us to constantly seek out progressive ways to provide a safe and fulfilling environment for our residents and staff,” said Doug Leidig, Chief Operating Officer of Asbury Communities. “We found that MPSRx had the level of technology and the service commitment necessary to match our challenges and standards of excellence.”

MPSRx is the leading pharmacy services company to offer the long-term care industry solutions to enhance resident safety and improve nursing convenience while allowing real-time capture of resident data. The web-based, paperless technology improves quality results while increasing caregiver (RN, LPN, MD) efficiency and productivity that enhances resident and medical staff satisfaction.

According to MPSRx President and CEO Gary Duty, this contract reinforces the fact that quality long-term care providers are poised to invest in proven technology to provide the safest possible environment for their residents.

“Asbury Communities' fundamental philosophy related to resident safety, nursing efficiency and superior customer satisfaction is fully aligned with the products and services that are offered by MPSRx. We're very pleased that Asbury, after a thorough evaluation of services and technologies available in the marketplace, chose to establish a strategic partnership with our company,” said Mr. Duty.

“This partnership also confirms the long-term care industry's interest in embracing technology that improves quality and streamlines the medication management process. And, with our ongoing commitment to Making Pharmacies Safer and Making Patients Safer, we are positioned to meet the growing demand,” Mr. Duty added.

For further information regarding Asbury Communities, please contact Eric Anderson, Marketing and Communications Manager, at (301) 987-6173, via email at eanderson@asbury.org , or visit www.asbury.org. For information about Millennium Pharmacy Systems, Inc., please visit www.mpsrx.com.

VaxInnate Secures $40 Million Series C Financing; Funds Will Support Commercial Development of Novel Human and Avian Flu Vaccines
Cranbury, NJ – October 25, 2006

VaxInnate Corporation announced today that it has secured $40 million in a Series C financing. The company is developing novel, proprietary vaccines for both pandemic and seasonal influenza based on its Toll-like receptor (TLR) technology platform. VaxInnate's platform has the potential to substantially improve vaccine immunogenicity and efficacy while greatly reducing manufacturing costs. The funds raised will be used for the continued development of the company's vaccines for human and avian flu, as well as vaccines for other prophylactic and therapeutic applications.

New Leaf Venture Partners led the round, joined by Canaan Partners. Existing investors HealthCare Ventures, Oxford Bioscience Partners LLC, MedImmune Ventures, Inc., and CHL Medical Partners also participated in this round.

The U.S. Center for Disease Control and Prevention (CDC) reports that about five to twenty percent of the U.S. population contracts influenza each year. Of those people, more than 200,000 are hospitalized from flu complications and 25,000 to 50,000 die from the flu in a typical winter's flu season. Emerging threats of pandemic flu reinforce the need for technology that enables a robust, quick response. VaxInnate will use its TLR technology platform to produce vaccines by simple, low-cost, highly-scalable recombinant DNA techniques, avoiding the pitfalls of egg-based or cell-culture influenza vaccine production. The company's TLR technology enhances the immunogenicity of a series of antigens, which can be combined into a number of different influenza products.

“Influenza is one of the most communicable types of diseases, and yet one of the most challenging to prepare for on a large scale - due to both the variability of strains and the protracted manufacturing cycle. Our TLR technology platform offers a highly efficient and effective way to address both of these key issues, while enhancing vaccine potency and immunogenicity,” said Alan Shaw, President and CEO of VaxInnate. “We've been fortunate to attract excellent investors and a lot of interest in VaxInnate as part of this process. The additional funding will help us to continue advancing our human and avian flu vaccine candidates to market in the coming years, and support the development of other promising vaccine applications based on our proprietary technology.”

Philippe Chambon MD. PhD., Managing Director of New Leaf Venture Partners, stated, “VaxInnate combines a paradigm-shifting vaccine technology platform with a seasoned management team that has direct experience in successfully developing and bringing vaccines to market. The company has a broad pipeline of influenza and other vaccine products, which we believe will have a significant impact on public health.”

Seth Rudnick, General Partner of Canaan Partners, continued by saying, “This is an opportune time for new approaches to vaccine development to emerge. The industry, government, and public sector are all working together to investigate options to improve and shore up our vaccine supply in the near term but also make long term improvements. We believe that VaxInnate's approach and products under development are uniquely positioned to address key challenges in the marketplace.”

Philippe Chambon MD. PhD., Managing Director of New Leaf Venture Partners, and Seth Rudnick MD, General Partner of Canaan Partners, joined VaxInnate's Board of Directors.

Seaview Securities of New York served as the placement agent for the financing.

About VaxInnate
VaxInnate is a privately-held biotechnology company focused on developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's Toll-like receptor (TLR) technology platform allows for genetic engineering of the vaccines using recombinant DNA techniques. This technology physically links TLR agonists to vaccine antigens, which allows the conjugated vaccine to trigger an adaptive immune response. VaxInnate is using its TLR platform technology to enhance the immunogenicity of a series of antigens which will be combined into a number of different influenza products. The technology platform is also being investigated for development of vaccines for other diseases. For more information on VaxInnate, please visit http://www.vaxinnate.com.

VaxInnate Reports Promising Results for Novel Influenza Vaccine Candidates; Early Testing Demonstrates Company's Innovative Technology Yields Strong Immunogenicty
Cranbury, NJ – October 23, 2006

Two novel influenza vaccine candidates produced through an innovative technology have shown promising results in early testing, according to a presentation made by VaxInnate at the second "Influenza Vaccines for the World" conference. VaxInnate reported that vaccines fusing proteins or protein fragments from influenza virus with a protein from bacteria, and produced in a bacterial expression system, were able to deliver a highly efficacious response in mice.

VaxInnate reported that its seasonal influenza vaccine candidate based upon the hemagglutinin antigen (HA) showed good efficacy in mouse studies at low doses, providing complete protection against lethal influenza challenge at a dose of influenza that typically kills 90 percent of animals. Investigators attribute the effectiveness of the vaccine candidate to the fusion or linking of HA antigen to bacterial flagellin (STF2), a component of the hair-like tails that bacteria use to "swim." Flagellin is a toll-like receptor (TLR) ligand that stimulates the innate immune system – a first line defense against pathogens, which in turn triggers a more potent response from the adaptive immune system, including the production of antibodies and cytotoxic T cells. Neither the HA fragment alone, nor HA fragment plus flagellin administered simultaneously, were able to confer any significant protection against lethal influenza challenge demonstrating the importance of linking these two components.

Presenting HA fused with a bacterial TLR ligand, the vaccine represents a strategy for protecting against influenza infection by targeting seasonal variants of the virus. Each strain of influenza virus is characterized by its mutations that arise in proteins on its surface, including the HA molecule.

"This is the first proof-of-concept demonstration that shows physically linking bacterial flagellin to viral antigens leads to a more potent vaccine, harnessing the natural, synergistic relationship between the innate and adaptive immune response," said Lynda Tussey, Ph.D., Project Leader and Senior Director, Clinical Immunology at VaxInnate.

VaxInnate is also developing influenza vaccine candidates based upon the M2e antigen. Unlike traditional influenza vaccines using HA, the M2e vaccine candidate targets regions of the influenza virus that are highly conserved across all strains and would not require annual reformulation as do current vaccines. This product also links M2e antigen to STF2, inducing strong immune responses in mice that protect 90 percent of mice against lethal influenza challenge.

VaxInnate's vaccines are produced in a bacterial expression system, a proven method for producing large quantities of proteins that has been practiced for over two decades. Data presented at the conference showed that using this expression system, researchers have been able to consistently produce, harvest and purify folded vaccine fusion products in large quantity and high purity. The technology is also potentially much more efficient than current influenza vaccine production methods. Current yields suggest 50 million to 100 million doses can be produced per standard 2000 liter fermenter run.

"We believe that VaxInnate's technology has the potential to significantly improve the cost-effectiveness, manufacturing capacity, and potency of influenza vaccines, key issues facing the clinical and public health communities," said Dr. Tussey. "We look forward to continued advancement of our vaccine candidates as an important contribution to the global response to influenza and pandemic preparedness."

The IVW conference is an international forum for world renowned experts in the field of influenza vaccines and related issues to report the latest data and trends associated with current and new influenza vaccines and their delivery worldwide.

About VaxInnate
VaxInnate is a privately-held biotechnology company based in Cranbury, NJ that is developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy. For more information about VaxInnate, please visit http://www.vaxinnate.com.

Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications
South San Francisco, CA and Branford, CT – October 3, 2006

Genentech, Inc. and CGI Pharmaceuticals, Inc. announced today that they have entered into an exclusive global collaboration agreement to discover, develop, manufacture and commercialize therapeutics for an undisclosed target for the potential treatment of multiple oncology and autoimmune indications.

Under the terms of the multi-year agreement, Genentech makes an upfront payment to CGI of $25 million, comprised of both license fees and an equity investment in CGI. Genentech obtains an exclusive license to discover, develop and market small molecules based on the target throughout the world, except in the states of the European Union. In the EU, CGI retains the right (independently or in conjunction with Genentech) to develop and commercialize potential molecules arising from the collaboration. The agreement includes opportunities for further expansion of the collaboration, with the potential for CGI to receive milestone and option payments in excess of $500 million upon the successful completion of certain development and regulatory milestones. The companies did not disclose further financial terms of the agreement.

"CGI has committed itself to developing a highly novel approach in a very important area of biology," stated Michael Varney, Genentech vice president, Small Molecule Drug Discovery. "This collaboration supports Genentech's goal of aggressively pursuing novel and innovative therapies, small or large molecules, to important oncology or autoimmune diseases."

"We are very pleased to be working with Genentech, as this collaboration is very nicely crafted to take advantage of both parties' expertise," said Peter Fuller, Ph.D., CGI's COO. "The combination of Genentech's expertise in biology and our understanding of the chemistry underlying this target, we believe, provides this program with the potential to bring new therapies to market," added Mark Velleca, MD, Ph.D., CGI's CSO.

About CGI Pharmaceuticals
CGI Pharmaceuticals, Inc. is a private, development-stage pharmaceutical company that has leveraged its small molecule chemistry and kinase biology expertise to discover and develop an innovative pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. CGI's oncology drug development candidate, cgi1842, targets a unique combination of kinases that are critical for tumor angiogenesis. CGI's corporate headquarters and research laboratories are located in Branford, Connecticut. For additional information about the company, please visit: http://www.cgipharma.com.

About Genentech
Founded 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.

Amicus Therapeutics Appoints New Chief Financial Officer
Cranbury, NJ – October 2, 2006

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the appointment of James E. Dentzer as Chief Financial Officer (CFO). Mr. Dentzer joins Amicus from Biogen Idec Inc., where he served as Vice President and Corporate Controller.

“Jim has outstanding experience in the pharmaceutical and consumer products industries,” stated Donald J. Hayden, Jr., Executive Chairman and interim President and CEO of Amicus. “He is a great addition to what is already an excellent management team at Amicus and I know he will contribute significantly to the continued growth and success of the company.”

Prior to joining Biogen Idec, Mr. Dentzer served in a variety of financial positions at E. I. du Pont de Nemours and Company, including serving as Chief Financial Officer of DuPont Flooring Systems. Mr. Dentzer also held various positions at Kemper Financial Services and at Bank of Boston. Mr. Dentzer received a B.A. from Boston College and an M.B.A. from the University of Chicago.

About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded proteins caused by genetic mutations. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus' is currently conducting Phase II clinical trials for its lead compound, Amigal™, for Fabry disease, and is conducting Phase I clinical trials of AT2101 for Gaucher disease. The company also plans to file an IND for AT2220 for the treatment of Pompe disease in the second half of 2006.

Medicus Insurance Holdings, Inc. Secures Funding from The Cypress Group and CHL Medical Partners; New Insurance Company To Target Professional Medical-Liability Market
Austin, TX – October 2, 2006

Medicus Insurance Holdings, Inc. announced today that it has entered into a financing arrangement with institutional investors for the issuance of up to $100 million of Series A Preferred Stock. Medicus and its operating subsidiary, Medicus Insurance Company, were formed in order to provide a new source of professional medical-liability insurance coverage to physicians in Texas and other states.

In the first round of funding Medicus Insurance Holdings, Inc. received $15 million, with subsequent rounds to support growth expected over the next three years. Sponsoring investors of Medicus are affiliates of The Cypress Group and CHL Medical Partners. The Medicus management team, led by Howard H. Lamb and Sheldon Davidow, has also made a significant investment in the company.

The Medicus management team has extensive industry experience and local roots in the Texas market. Over the course of his 50-year career in the insurance industry, Medicus CEO Howard Lamb served as CEO of The Doctors Company and held other senior leadership positions in the insurance industry. Medicus President and Chief Operating Officer Sheldon Davidow has over 25 years of insurance industry experience and has worked with Mr. Lamb previously as Executive Vice President of The Doctors Company. Charles W. Bailey, Jr., M.D., J.D., former President of the Texas Medical Association, will serve as the company's Vice President of Medical Relations.

"Medicus offers the medical community a compelling combination of a highly experienced management team supported by a substantial capital base,” said Howard Lamb. “We look forward to becoming the insurer of choice for physicians in Texas and plan to earn their confidence by delivering quality, service, and value in our product offerings.” Speaking on behalf of the investor group, Walter Keenan of The Cypress Group said, “We congratulate Howard and Sheldon for assembling an extraordinary team of industry professionals at Medicus and for becoming a fully licensed and admitted carrier in the state of Texas. We are grateful for the encouraging response to Medicus' startup from doctors and their agents, and look forward to supporting the company's future growth.”

The shares of common stock and Series A Preferred Stock of Medicus Insurance Holdings, Inc. have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering would be unlawful.

About Medicus Insurance Company
Medicus Insurance Holdings, Inc. is a Delaware holding company whose sole subsidiary, Medicus Insurance Company, offers malpractice insurance to physicians, surgeons, and related medical-service providers in the state of Texas. The Medicus leadership team is comprised of insurance and medical leaders dedicated to providing lower-priced malpractice coverage that supports and protects medical practitioners in today's complex healthcare environment.

Studies Published in PNAS on the Mechanism of Amicus Therapeutics' Experimental Treatment for Gaucher Disease
Cranbury, NJ – September 20, 2006

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced that studies of the mechanism of action of its investigational treatment for Gaucher disease were published in the September 12 edition of the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Gaucher disease results from an inherited genetic mutation, which causes a deficiency in the key enzyme acid b-glucosidase, also known as glucocerebrosidase (GCase). AT2101, Amicus' lead compound for Gaucher disease, is designed to selectively bind to the GCase enzyme and help it fold into its correct three-dimensional shape. This binding and stabilization helps increase the proper movement of the enzyme from the endoplasmic reticulum (ER) to the lysosomes, the compartments in the cell where it performs its intended biological function.

In the current study, researchers performed several experiments with AT2101 on fibroblasts from a Gaucher patient with one of the most common disease-causing mutations, designated as N370S. After discovering that N370S GCase activity was increased in cells by as much as three-fold by AT2101 treatment for five days, researchers sought to understand in more detail the mechanisms by which AT2101 increased cellular GCase activity. Among the key findings:

- AT2101 facilitates proper folding, prevents premature degradation, and restores efficient transport of newly-synthesized N370S GCase to the lysosomes

- AT2101 increases the total amount of N370S GCase in the lysosomes and also leads to improved enzyme activity and lysosomal stability

“We've known for some time that the pharmacological chaperone AT2101 increases the activity of the key enzyme deficient in Gaucher patients, but now we have evidence of how it actually works, which is very exciting,” said study investigator Stuart A. Kornfeld, M.D., Washington University School of Medicine, St. Louis. “There is a real need for new treatment options for Gaucher disease, and these study results are very promising.”

Amicus has filed an investigational new drug application for AT2101 for the treatment of Gaucher disease and Phase I clinical trials are underway.

About Gaucher Disease
Gaucher disease is the most common lysosomal storage disorder, affecting an estimated 8,000-10,000 people worldwide. Symptoms can be severe and debilitating, including an enlarged liver and spleen, abnormally low levels of red blood cells and platelets, and skeletal disease. In rare cases, there can be significant impairment of the central nervous system.

About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to a misfolded protein caused by a genetic mutation. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical need. Amicus' lead compound Amigal™ is in Phase II clinical trials for the treatment of Fabry disease. The company has filed an IND for AT2101 for the treatment of Gaucher disease and has initiated Phase I clinical trials. The company plans to file an IND for AT2220 for the treatment of Pompe disease in the second half of 2006.

Amicus Therapeutics Raises $60 Million Series D Financing
Cranbury, NJ – September 14, 2006

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the closing of a $60 million Series D financing, the Company's largest to date, led by New Enterprise Associates (NEA). In August, due to market conditions, the Company withdrew its S-1 registration statement with the Securities and Exchange Commission (SEC) relating to a proposed initial public offering.

In this financing round, NEA was joined by current investors Canaan Partners, CHL Medical Partners, Frazier Healthcare Ventures, Palo Alto Investors, Prospect Venture Partners, Quaker BioVentures, and Radius Ventures. In addition, affiliated investment funds of Och-Ziff Capital Management Group participated in this round of financing as a new investor.

Amicus also announced today two key executive management appointments. First, Donald J. Hayden, Jr., Executive Chairman, will serve as Interim President and Chief Executive Officer while John F. Crowley, President and CEO, serves a six-month active duty military obligation with the United States Navy. He is a commissioned officer in the Navy Reserve. Mr. Crowley will return as the CEO on or about March 1st, 2007. Second, Matthew R. Patterson has been promoted from Chief Business Officer to Chief Operating Officer.

”I am delighted that Amicus has been able to secure our largest financing round to date. Our core investors clearly believe in the Company's pharmacological chaperone technology. We are also extremely pleased to have Och-Ziff Capital Management Group onboard as our newest investor. This additional funding will enable us to continue to advance our pipeline of potential new treatments for the lysosomal storage disorders Fabry, Gaucher, and Pompe and to aggressively develop our earlier stage programs for other genetic diseases. Additionally, I am honored to be asked to serve my country during this active duty obligation and I have the utmost confidence that Don Hayden and the extraordinary senior management team at Amicus will continue to move the company forward while I am away,” said John F. Crowley.

“We are extremely pleased to make this additional investment that will further enable Amicus' dynamic growth and lay the foundation for a significant and enduring enterprise. The speed and high quality of execution are a testament to the outstanding efforts of this well led and capable team. We wish John Crowley the best of luck during his six-month military service and look forward to his return next spring,” said Michael G. Raab, Partner at NEA and member of Amicus' Board of Directors.

About Donald J. Hayden, Jr.
Mr. Hayden brings to Amicus the experiences, insights, and perspective gained during a highly successful 25-year career in pharmaceuticals and related health care businesses with Bristol-Myers Squibb Company, including 15 years in senior executive positions. Mr. Hayden has a proven track record of innovative strategy development, growing successful products and businesses, and building exceptional leadership teams.

During his career at Bristol-Myers Squibb, Mr. Hayden held key positions such as: president of Oncology and Immunology; senior vice president for Worldwide Franchise Management and Business Development; president of Intercontinental and senior vice president, Business Development, Pharmaceuticals; president of Worldwide Medicines; executive vice president of Strategy; and executive vice president of the Health Care Group. For the past four years, Mr. Hayden served as executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses with combined annual sales in excess of $10 billion, as well as global pharmaceutical manufacturing. He received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.

Mr. Hayden joined Amicus as Executive Chairman in March of this year. Over the past six months he has played an important role in guiding the work of the Board of Directors while working closely with senior management on business strategy and leadership development.

About Matthew R. Patterson
Mr. Patterson joined Amicus in December 2004 and served as Chief Business Officer prior to being promoted to Chief Operating Officer. Mr. Patterson previously served as vice president of Regulatory Affairs, and later vice president of Commercial Planning, at BioMarin Pharmaceutical. Mr. Patterson oversaw the development of Aldurazyme® (laronidase) for the treatment of the genetic disease MPS I and helped build the sales and marketing function for the company. Prior to BioMarin, Mr. Patterson worked at Genzyme Corporation in Manufacturing and Regulatory Affairs. While at Genzyme, he contributed to the development and global licensing of multiple products. Mr. Patterson received his B.A. in Biochemistry from Bowdoin College.

About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to a misfolded protein caused by a genetic mutation. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical need. Amicus' lead compound Amigal™ is in Phase II clinical trials for the treatment of Fabry disease. The company has filed an IND for AT2101 for the treatment of Gaucher disease and has initiated Phase I clinical trials. The company plans to file an IND for AT2220 for the treatment of Pompe disease in the second half of 2006.

Amicus Therapeutics Adds Glenn P. Sblendorio to Board of Directors; Company Makes Executive and Management Appointments
Cranbury, NJ – July 5, 2006

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the appointment of Glenn P. Sblendorio to its Board of Directors. Mr. Sblendorio will serve as the financial expert on the Board and will act as Chair of the audit committee. In addition, the company appointed Mark J. Simon as Senior Vice President of Business Development, promoted Douglas A. Branch to Vice President, General Counsel and Secretary, and hired Jayne Gershkowitz as Director, Public Policy.

“Amicus is pleased to welcome these four highly accomplished executives to our Board and management team,” stated John F. Crowley, President and CEO of Amicus. “Their shared expertise and strong leadership skills will be invaluable as the Company continues its rapid growth and its development of new treatments for a range of human genetic diseases.”

About Glenn Sblendorio
Mr. Sblendorio joins the Amicus Board of Directors as the financial expert and will act as Chair of the audit committee. He currently serves as the Chief Financial Officer and Executive Vice President for The Medicines Company. Prior to joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as Senior Vice President of Business Development for The Medicines Company. From 1998 to July 2000, Mr. Sblendorio was the Chief Executive Officer and Managing Director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen/Roche Europe. Mr. Sblendorio is also Chairman of NuLens Ltd., a medical device company that develops and manufactures intra-ocular lenses.

About Mark Simon
Mr. Simon joins the Amicus team as Senior Vice President of Business Development, after serving the Company as a consultant since February 2006. Mr. Simon has been serving as a consultant to multiple biopharmaceutical companies since October 2005. From 2002 to 2005, Mr. Simon served as Managing Director and Head of Life Sciences Investment Banking for Citigroup Global Markets. From 1988-2002, Mr. Simon served as a Senior Research Analyst and later as Managing Director, Investment Banking for Robertson Stephens.

About Douglas Branch
Mr. Branch has been promoted to the position of Vice President, General Counsel and Secretary after serving the company since December 2005 as General Counsel and Secretary. He also serves as President of Biotech Law Associates, P.C., a law firm representing emerging life science companies, and before founding that firm, he was a Director and Shareholder in Phillips McFall McCaffrey McVay & Murrah, P.C., an Oklahoma City law firm. He is the former Chairman of the Oklahoma Center for the Advancement of Science and Technology.

About Jayne Gershkowitz
Ms. Gershkowitz joined Amicus as Director, Public Policy after serving as National Executive Director of the National-Tay Sachs & Allied Diseases Association, Inc. (NTSAD), since 1998. Prior to NTSAD, Ms. Gershkowitz was Director of Marketing and Communications at Jewish Family & Children's Service of Greater Boston from 1991-1998. Ms. Gershkowitz recently held positions as Vice Chair of the Board of Directors of the National Organization for Rare Disorders, Vice Chair of the Management Council of the Global Organisation for Lysosomal Diseases, and is co-founder of the Lysosomal Storage Disease Research Consortium.

About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to a misfolded protein caused by a genetic mutation. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical need. Amicus is currently conducting Phase II clinical trials for its lead compound, Amigal™, for Fabry disease, and is conducting Phase I clinical trials of AT2101 for Gaucher disease. The company plans to file an IND for AT2220 for the treatment of Pompe disease in the second half of 2006.

Safe Harbor Statement
This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words "may," "believes," "will", "expects," "anticipates," or the negation thereof, or similar expressions, which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Amicus to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For those statements, Amicus claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. Amicus will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Ivrea Pharmaceuticals Raises $11 Million for Clinical Development
Qunicy, MA – June 30, 2006

Ivrea Pharmaceuticals, an emerging specialty pharmaceutical company focusing on dermatology, today announced it raised $11 million from existing investors Atlas Venture and Easton Capital and new investor CHL Medical Partners.

"Our existing investors and CHL Medical Partners recognize the immense potential of the two compounds we have in the clinic. Their support will enable IVREA to advance these two programs beyond Phase II clinical development," said Michael Kobos, President and CEO of IVREA Pharmaceuticals.

With the closing of the financing, Myles Greenberg, M.D., of CHL Medical Partners will join existing Board members, Michael Kobos, CEO, Seth Orlow, M.D., Ph.D., Chair of the Department of Dermatology at NYU, Scott Silverman, D.Phil. and Peter Barrett, Ph.D. of Atlas Venture and Frank Garcia of Easton Capital.

Spine Wave Begins Patient Enrollment in NuCore™ Injectable Nucleus Degenerative Disc Disease Feasibility Study
Shelton, CT – June 28, 2006

Spine Wave, Inc. announced today that it has begun patient enrollment in a second arm of a feasibility IDE clinical trial studying the company’s proprietary NuCore™ Injectable Nucleus for the treatment of Degenerative Disc Disease (DDD). Earlier this year, the Company announced that it had begun the first arm of an IDE clinical trial of the NuCore™ Injectable Nucleus for use as an adjunct to microdiscectomy.

DDD is a gradual process that occurs as an individual ages, causing low back pain for millions of people. In this IDE study, the surgeon will make a small incision and then use a needle to inject the NuCore™ Injectable Nucleus into the damaged disc. The NuCore™ material is injected in a liquid form which rapidly cures to a gel.

Hyun W. Bae, M.D., a spine surgeon on staff at St. John’s Hospital and Century City Doctors Hospital in Los Angeles, is the Principal Investigator in this arm of the IDE study. “I am excited to begin treating patients in this study”, stated Dr. Bae. “This procedure holds great promise for millions of Americans who suffer from back pain caused by disc degeneration. We currently can either fuse the discs together or implant an artificial disc to provide relief for patients. This new procedure allows a surgeon to use a needle to inject the NuCore™ material and in so doing, ‘pump up’ the nucleus that separates the vertebrae and cushions the spine. It may be performed as an outpatient procedure and be more suitable for the patient who is not yet a candidate for major spine surgery.”

The NuCore™ Injectable Nucleus was developed in conjunction with Spine Wave’s technology partner, Protein Polymer Technologies Inc (PPTI). Spine Wave holds an exclusive license to 26 patents and other patent applications pending in the United States and internationally in the fields of Spine and Orthopedics. The NuCore™ Injectable Nucleus was developed to replace the degraded nucleus inside the disc. The NuCore™ Injectable Nucleus is an injectable, 100% synthetic recombinant protein hydrogel designed to mimic the natural nucleus and restore the spine’s natural biomechanics.

Spine Wave has now enrolled patients in DDD and microdiscectomy studies of the NuCore™ Injectable Nucleus in four countries: Switzerland, Australia, Germany, and the United States.

About Spine Wave
The Company is focused on the development and marketing of clinical solutions for three of the largest and fastest growing spinal market segments: nuclear replacement and augmentation, vertebral compression fracture repair and spinal fusion. The company’s product portfolio includes the NuCore™ Injectable Nucleus, the StaXx™ FX Fracture Repair System, the StaXx™ XD Expandable Device, and several additional products in development. In January 2006, Spine Wave closed a series C financing and raised $36.5 million, bringing the total funds raised to date to $90 million. For more information, visit Spine Wave’s website at www.spinewave.com.

Amicus Therapeutics Files for Initial Public Offering
Cranbury, NJ – May 17, 2006

Amicus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares in the offering will be sold by Amicus Therapeutics.

Morgan Stanley will act as sole book-runner and lead manager, Goldman, Sachs & Co. will act as joint lead manager, and Pacific Growth Equities, LLC will act as co-manager in the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. When available, a preliminary prospectus may be obtained from Morgan Stanley & Co. Incorporated, by emailing prospectus@morganstanley.com, or by contacting the prospectus department at Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, New York 10014, by telephone at 212-761-6775.

About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a wide range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to a misfolded protein caused by a genetic mutation. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical need. Amicus' lead compound Amigal™ is in Phase II clinical trials for the treatment of Fabry disease. The company has filed an IND for AT2101 for the treatment of Gaucher disease and intends to initiate Phase I clinical trials in the second half of 2006. The company plans to file an IND for AT2220 for the treatment of Pompe disease in the second half of 2006.

Safe Harbor Statement
This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words "may," "believes," "will", "expects," "anticipates," or the negation thereof, or similar expressions, which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Amicus to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For those statements, Amicus claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. Amicus will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Spine Wave Announces StaXx™ XD FDA 510(k) Clearance
Shelton, CT – May 4, 2006

Spine Wave announced today that the Company received FDA 510(k) clearance to market the StaXx™ XD Expandable Device. The innovative expandable PEEK spacer, indicated for use as a Vertebral Body Replacement device, will be the first commercial product that the Company will release into the U.S. market.

“We are excited to bring the StaXx™ XD System to the U.S. market and to begin building our U.S. distribution,” said Mark LoGuidice, Chairman and CEO of Spine Wave. “Surgeon response to the StaXx™ XD PEEK spacer, and in particular, the implant’s in situ expansion and distraction capabilities, has been very encouraging.”

Scott Kitchel, M.D., Assistant Clinical Professor of Orthopedic Surgery at Oregon Health and Sciences University added, “I have been working with the Company for several years developing this technology. I believe that the StaXx™ XD’s in situ distraction offers unique advantages not available with one-piece, monolithic implant designs and I am eager to begin using the system.”

Spine Wave expects to complete a StaXx™ XD limited U.S. release this summer with a broad market launch in the fall. Mr. LoGuidice commented, “We are in the process of aggressively recruiting a world class sales organization in preparation for the full market launch. We anticipate having a robust product portfolio and the StaXx™ XD System is simply the first of many products that we plan to leverage through our distribution.”

About Spine Wave
In January, Spine Wave closed a series C financing and raised an additional $36.5 million, bringing the total funds raised to date to $90 million. The Company is focused on the development and marketing of clinical solutions for three of the largest and fastest growing spinal market segments: nuclear replacement and augmentation, vertebral compression fracture repair and spinal fusion. The company’s product portfolio includes the NuCore™ Injectable Nucleus, the StaXx™ FX Fracture Repair System, the StaXx™ XD Expandable Device, and several additional products in development. For more information, visit Spine Wave’s website at www.spinewave.com.

Amicus Therapeutics Files Investigational New Drug Application for AT2101 for Gaucher Disease; Phase I Clinical Trial Expected to Commence in June.
Cranbury, NJ – April 27, 2006

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for AT2101 for the treatment of Gaucher disease. Pending FDA review of the IND, the company plans to begin Phase I clinical trials in June.

Gaucher disease is a lysosomal storage disorder that affects approximately 10,000 people in the developed world. Symptoms can be severe and debilitating, including an enlarged liver and spleen, abnormally low levels of red blood cells and platelets, and skeletal disease. In rare cases there can be significant impairment of the central nervous system. Gaucher disease is caused by a deficiency in the enzyme ß-glucocerebrosidase (GCase) resulting from an inherited genetic mutation. In most cases, this mutation causes GCase to be misfolded and unable to perform its normal function.

AT2101, taken orally, is designed to act as a pharmacological chaperone that binds to and stabilizes the misfolded GCase enzyme, which allows it to be transported to the lysosome where it is active and performs its normal function. In pre-clinical tests, AT2101 has shown the ability to increase GCase activity in cells with a variety of different mutations that cause Gaucher disease, including the most common type of mutation, which accounts for more than 50% of the patient population.

“Our patient organization looks forward to working with Amicus to ensure that the potential of this therapy is evaluated in human clinical trials”, said Rhonda Buyers, Executive Director, National Gaucher Foundation.

AT2101 for Gaucher disease is the second Amicus product to enter clinical trials. The company's lead compound, Amigal™ (migalastat hydrochloride), is a pharmacological chaperone in Phase ll clinical trials for Fabry disease.

In January 2006, Amicus received orphan drug designation for AT2101 from the FDA's Office of Orphan Products Development.

About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company based in Cranbury, New Jersey, developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases. Many of these diseases are the result of missense and other genetic errors that cause the misfolding and degradation or accumulation of a particular protein. Amicus' products act as pharmacological chaperones that selectively bind and “rescue” the misfolded target protein to restore its proper conformation and natural function, which in turn restores the function of the affected cells. Amicus' lead compound Amigal™ is in Phase II clinical trials for Fabry disease. The company has filed an IND for AT2101 for Gaucher disease, and is developing programs for a range of genetic diseases.

European Regulatory Committee Recommends Orphan Medicinal Product Designation for Amicus Therapeutics' Amigal™ for Fabry Disease.
Cranbury, NJ – April 11, 2006

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has recommended orphan medicinal product designation for Amigal™ (migalastat hydrochloride or AT1001).

Amigal™ is being developed as an oral therapy for the treatment of Fabry disease, a lysosomal storage disorder caused by an enzyme deficiency that leads to pain, kidney failure, and an increased risk of heart attack and stroke. Amigal™ is currently being studied in Phase II clinical trials in the U.S., the U.K., Brazil, and Australia.

Fabry disease affects approximately 5,000 to 10,000 people in the developed world, but recent evidence suggests that the disease may be significantly underdiagnosed. Orphan designation granted by the EMEA provides 10 years of market exclusivity after approval and other incentives to support and encourage development of drugs for diseases that affect fewer than five in every 10,000 people in the European Union (EU). Fabry disease affects an estimated 1.75 out of every 100,000 people in the EU. In addition, for diseases with an approved therapy in Europe, such as Fabry disease, a new therapy must have the potential to provide significant benefit over the existing therapy in order to receive orphan designation. The recommendation now goes to the European Commission for approval.

In February 2004, the Food and Drug Administration's Office of Orphan Products Development granted orphan designation for Amigal™ in the United States.

About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company based in Cranbury, New Jersey, developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases. Many of these diseases are the result of missense and other genetic errors that cause the misfolding and degradation or accumulation of a particular protein. Amicus' products act as pharmacological chaperones that selectively bind and “rescue” the misfolded target protein to restore its proper conformation and natural function, which in turn restores the function of the affected cells. Amicus' lead compound, Amigal™, is in Phase II clinical trials for Fabry disease. AT2101 for the treatment of Gaucher disease is expected to enter clinical studies in the first half of this year. The company is also developing programs for additional genetic diseases.

Spine Wave Further Strengthens Management Team; Announces Vice President of Sales
Shelton, CT – April 4, 2006

Spine Wave announced today the appointment of Nick Lake as Vice President, Sales. Mr. Lake brings 25 years of successful sales and sales management experience. He is charged with establishing the Company’s U.S. distribution and associated infrastructure as the Company prepares to introduce its first commercial product into the U.S. market. The company hopes to receive FDA 510(k) clearance on the StaXx™ XD System later this year.

“Nick possesses a rare combination of personal attributes that allow him to be universally liked and respected by peers, subordinates and customers alike,” said Mark LoGuidice, Chairman and CEO of Spine Wave. “Nick is known for his professionalism, integrity, work ethic, and most importantly, his ability to consistently deliver results. I have known Nick for over 20 years, having worked closely with him at both United States Surgical Corporation and Sofamor Danek Group. I am very confident that he will develop and lead a world class sales organization at Spine Wave.”

Mr. Lake was most recently U.S. President of Medtronic Neurologic Technologies where he was one of the founding executives. He was charged with the task of establishing a new sales organization by integrating the sales group associated with the Midas Rex, PS Medical, and TiMesh technologies. Prior to joining Medtronic Neurologic Technologies, Mr. Lake was an Area Vice President of Sales for both Sofamor Danek and United States Surgical Corporation.

“When I was approached by Mark, I was very impressed with the Company’s portfolio of products, outstanding investor syndicate, and the management team that had been assembled,” said Mr. Lake. “I am excited to join Spine Wave and I am eager to build the U.S. distribution.”

Commenting on the overall management team, Mr. LoGuidice said “We continue to attract top talent to further strengthen our management team. The addition of Nick is one of the final pieces needed to position Spine Wave for the growth that we and our investors expect.”

Spine Wave has aggressively strengthened its management team in the last 6 months in preparation for the Company’s first general market release and the further advancement of their clinical programs. Anthony James and Peter Carlyle both joined Spine Wave in September 2005 as VP of R&D, Fracture & Fusion, and VP of Clinical Affairs, respectively. Mr. James joins Spine Wave after an exceptional 18 year career at Smith & Nephew where he was most recently VP of R&D Trauma, and was responsible for products generating over $400 million in annual worldwide sales. Mr. Carlyle brings 20 years of successful clinical experience including service as VP of Clinical Affairs for Edwards Lifesciences and Director of Clinical Affairs at Medtronic AVE.

“It’s a very strong team of people managing a product portfolio with huge potential,” said Mr. LoGuidice.” We are expecting 2006 to be a very exciting year for us.”

About Spine Wave
In January, Spine Wave closed a series C financing and raised an additional $36.5 million, bringing the total funds raised to date to $90 million. The Company is focused on the development and marketing of clinical solutions for three of the largest and fastest growing spinal market segments: nuclear replacement and augmentation, vertebral compression fracture repair and spinal fusion. The company’s product portfolio includes the NuCore™ Injectable Nucleus, the StaXx™ FX Fracture Repair System, the StaXx™ XD Expandable Device, and several additional products in development. For more information, visit Spine Wave’s website at www.spinewave.com.

Amicus Therapeutics Appoints Pharmaceutical Veteran Donald Hayden, Jr. Executive Chairman of Its Board of Directors.
Cranbury, NJ – March 31, 2006

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-delivered pharmacological chaperones for the treatment of human genetic diseases, today announced the appointment of Donald J. Hayden, Jr. as executive chairman of the company's Board of Directors. Mr. Hayden brings to Amicus the experience, insight and perspective gained during a highly-successful 25 year career in pharmaceuticals and related health care businesses with Bristol-Myers Squibb Company, including 15 years in senior executive positions. Mr. Hayden has a proven track record of innovative strategy development, growing successful products and businesses and building exceptional leadership teams.

“Don brings an impressive pharmaceutical background to Amicus, and as executive chairman he will use his considerable industry experience to help Amicus grow, develop and commercialize our paradigm-shifting pharmacological chaperones,” said John F. Crowley, Amicus president and CEO. “Don and I have a long-standing relationship from my own days at BMS, and I am very pleased personally and on behalf of the company that we will be working together again.”

Mr. Hayden began his career as a business intern with Bristol-Myers Squibb in 1981. His early career experiences included serving as director of new business development and planning for the U.S. Pharmaceutical Group, as director of marketing for Mead Johnson Pharmaceuticals and as a district sales manager within the BMS oncology division. Since 1991 Mr. Hayden has held a number of senior management positions including vice president and general manager of Mead Johnson Laboratories; president of Oncology and Immunology; senior vice president for Worldwide Franchise Management and Business Development; president of Intercontinental and senior vice president, Business Development, Pharmaceuticals; president of Worldwide Medicines; executive vice president of Strategy, e-business, Investor Relations and Competitive Intelligence; and executive vice president of the Health Care Group. For the past four years, Mr. Hayden served as executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses with combined annual sales in excess of $10 billion as well as global pharmaceutical manufacturing. Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.

“Amicus has a truly novel approach to treating genetic disorders supported by early clinical and preclinical data, and I look forward to helping the company bring important new therapeutics to the market and to the patients who need them,” said Mr. Hayden. “I am particularly pleased to have the chance to apply my pharmaceutical experience to the opportunities and challenges of growing Amicus into one of the world's leading biotechnology companies.”

Added Alex Barkas, Ph.D., Amicus board member and managing director, Prospect Venture Partners, “This is an exciting time for Amicus as we continue to advance our work in the clinic and expand our pipeline. Don will be an invaluable asset through his expert advice and guidance as we chart the company's course for the future.”

Amicus develops pharmacological chaperones, a next-generation approach that offers the potential to dramatically improve treatment options for patients with a wide range of genetic disorders. Pharmacological chaperones are orally-delivered small molecules that selectively bind to misfolded proteins to restore shape, proper trafficking and biological function. Amicus' lead compound Amigal™ (migalastat hydrochloride) is in Phase ll clinical trials for Fabry disease, and AT2101, with orphan drug designation for treating Gaucher disease, is expected to enter clinical studies in the first half of this year.

Spine Wave Begins Patient Enrollment in NuCore™ Injectable Nucleus Clinical Trial
Shelton, CT– February 21, 2006

Spine Wave, Inc. announced today that it has begun patient enrollment in a feasibility IDE clinical trial studying the company’s proprietary NuCore™ Injectable Nucleus. Spine Wave believes that NuCore™ Injectable Nucleus is the first injectable spinal nucleus device to be implanted into patients within an FDA
approved study. In this IDE study, the NuCore™ Injectable Nucleus will be implanted following a standard microdiscectomy procedure in order to fill the void created when herniated nuclear material is surgically removed from the disc. The NuCore™ material is injected in liquid form then rapidly cures to a gel that has physical properties similar to those of the natural nucleus. The goal of the procedure is to supplement the remaining natural nucleus and in so doing, restore the normal biomechanics of the disc.

Scott Kitchel, M.D., Assistant Clinical Professor of Orthopedic Surgery at Oregon Health and Sciences University, is the Principal Investigator in this study. “I am excited to participate in this study”, stated Dr. Kitchel. “This is one of the most exciting technologies I have seen in the field of spine and I am very encouraged by the early study results coming out of Europe. Unlike many other spinal implants, the injectable nature of the NuCore™ material allows it to be used in a minimally invasive fashion, therefore minimizing damage to the surrounding tissues. The NuCore™ Injectable Nucleus has the potential to help thousands of patients who suffer from back and associated leg pain."

The NuCore™ Injectable Nucleus was developed in conjunction with Spine Wave’s technology partner, Protein Polymer Technologies Inc (PPTI). Spine Wave holds an exclusive license to 26 patents and other patent applications pending in the United States and internationally in the fields of Spine and Orthopedics. The material is a synthetic protein copolymer, and as such, contains no animal or human components. The physical properties of the NuCore™ Injectable Nucleus, including stiffness and water content, are engineered to be similar to those of the natural nucleus.

Spine Wave has now enrolled patients in microdiscectomy studies of NuCore™
Injectable Nucleus in four countries: Switzerland, Australia, Germany, and the United States, and expects to expand enrollment of these and other studies in the first half of 2006. The Company also expects to initiate enrollment in European clinical studies to assess the potential of the NuCore™ Injectable Nucleus to help treat patients suffering from Degenerative Disc Disease.

About Spine Wave
Spine Wave is a medical device company focused on the development and marketing of clinical solutions for three of the largest and fastest growing spinal market segments: nuclear replacement and augmentation, vertebral compression fracture repair and spinal fusion. The company’s product portfolio includes the NuCore™ Injectable Nucleus, the StaXx™ FX Fracture Repair System, the StaXx™ XD Expandable Device, and several products in development. For more information, visit Spine Wave’s website at www.spinewave.com.

Amicus Therapeutics' AT2101 Granted Orphan Drug Designation for the Treatment of Gaucher Disease.
Cranbury, NJ – February 15, 2006

Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that AT2101 has received orphan drug designation from the U.S. Food and Drug Administration. AT2101 is an experimental, oral therapy for the treatment of Gaucher disease, a lysosomal storage disorder resulting from an enzyme deficiency that can cause damage to the liver, spleen, bone marrow and in some cases, the central nervous system. Gaucher disease affects approximately 10,000 people in the developed world. Orphan drug designation provides extended marketing rights and other incentives to support and encourage development of drugs that affect fewer than 200,000 people annually in the United States.

AT2101 acts as a pharmacological chaperone that binds to glucocerebrosidase (GCase), the enzyme involved in Gaucher disease. In most Gaucher patients, the GCase deficiency is caused by a missense mutation, which results in the misfolding and degradation of the protein. As a pharmacological chaperone, AT2101 binds specifically to the misfolded protein, which in turn restores proper structure, trafficking and biological activity.

AT2101 is expected to enter clinical studies in the first half of this year.

Amicus' lead compound Amigal™ (migalastat hydrochloride) is a pharmacological chaperone in Phase ll clinical trials for Fabry disease, and the company has a growing pipeline of other products for a range of genetic diseases.

About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company based in Cranbury, New Jersey, developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases. Many of these diseases are the result of missense and other genetic errors that cause the misfolding and degradation or accumulation of a particular protein. Amicus' products act as pharmacological chaperones that selectively bind and “rescue” the misfolded target protein to restore its proper conformation and natural function, which in turn restores the function of the affected cells. Amicus' lead compound Amigal™ is in Phase II clinical trials for Fabry disease. The company has an active drug development program for Gaucher disease and is developing programs for a range of genetic diseases.

Becton Dickinson Completes Acquisition of GeneOhm Sciences, Inc.
Franklin Lakes, NJ – February 14, 2006

Becton, Dickinson and Company (NYSE:BDX) today announced the completion of its acquisition of GeneOhm Sciences, Inc., a pioneer in the development of molecular diagnostic testing for the rapid detection of bacterial organisms, including those known to cause healthcare-associated infections (HAIs), a growing global healthcare problem. The acquisition was finalized in accordance with terms originally disclosed in an announcement issued by BD on January 10, 2006.

The acquisition of GeneOhm Sciences is a natural complement to BD's core strengths in microbiology and validates its commitment to expansion in molecular diagnostics. It will enable BD to move quickly into the emerging HAI field and positions the company to become a leader in the prevention of this global healthcare problem.

BD will implement a broad, global initiative to work with hospitals, governments and other related parties to address the challenge of reducing HAIs. The GeneOhm Sciences array of rapid molecular assays for detection of these “super bugs” will offer important tools to address the diagnostic challenge of providing almost immediate detection of these harmful, infection-causing organisms. Ensuring prompt identification of bacteria, such as MRSA (methicillin resistant Staphylococcus aureus), enables the appropriate and directed drug therapy to commence sooner, and it can significantly impact patient and economic outcomes, a primary customer expectation. BD expects to bring its proven educational, training and in-service resources to this problem to assist physicians, nurses and others in a highly collaborative effort to reduce illness and mortality associated with HAIs.

This acquisition further demonstrates BD's commitment to bringing new technologies and innovation to difficult problems in healthcare.

About Becton Dickinson
BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

Spine Wave Closes $36.5 Million Financing
Shelton, CT– February 9, 2006

Spine Wave, Inc., a developer of advanced materials, techniques, and implant systems for spine surgery, today announced the completion of a new $36,500,000 round of equity financing. The Series C round was led by existing
investor New Enterprise Associates with new investor Foundation Medical Partners. Also participating in the financing were existing investors Canaan Partners, Morgenthaler Venture Partners, Sprout Capital, Thoma Cressey Equity Partners, CHL Medical Partners and California Technology Partners.

“We are all very excited about this financing,” said Mark LoGuidice, Spine Wave’s CEO and Chairman. “We welcome the addition of Foundation Medical Partners to an already strong investor syndicate and we are particularly pleased with the confidence that NEA and all of our existing investors have continued to display in Spine Wave’s proprietary technologies and our ability to build a significant spine company. With this financing in place, the company is now well-positioned to further pursue our global clinical programs and to invest in building the commercial presence to support the launch of our first product, the StaXx™ XD Expandable Device. We are confident that 2006 will be a very exciting and productive year for Spine Wave.”

Ryan Drant, who represents NEA on the Spine Wave board of directors, commented, “Mark and the experienced team at Spine Wave have made excellent clinical development progress with products for three different large-market clinical indications: lumbar fusion, vertebral compression fracture repair and disc repair. We are pleased to work with this strong management team and to play a part in funding Spine Wave to bring these exciting new products to market.”

About Spine Wave
Spine Wave, Inc. is a medical device company focused on the development and marketing of clinical solutions for three of the largest and fastest growing spinal market segments: nuclear replacement and augmentation, vertebral compression fracture repair and spinal fusion. The company’s product portfolio includes the NuCore™ Injectable Nucleus, the StaXx™ FX Fracture Repair System, the StaXx™ XD Expandable Device, and several products in development. For more information, please visit www.spinewave.com.

Medicare Contractor Establishes Reimbursement Coverage Policy for Genomic Health's Oncotype DX™ Breast Cancer Test
Redwood City, CA – January 13, 2006

Genomic Health, Inc. (Nasdaq: GHDX) today announced that the National Heritage Insurance Company (NHIC), the contractor that administers Medicare programs in California, has established a positive coverage policy for the company's Oncotype DX™ breast cancer test, which quantifies the likelihood of breast cancer recurrence and predicts the likelihood of response to chemotherapy for a large portion of early-stage breast cancer patients. Medicare bills for Oncotype DX are currently billed through NHIC because the test is conducted by Genomic Health in its Redwood City, California clinical reference laboratory.

The policy covers women with node-negative breast cancer who have tumors that are estrogen receptor-positive, when Oncotype DX is used within six months of diagnosis and the intention to treat or not treat with adjuvant chemotherapy would be contingent, at least in part, on the results of the test. The NHIC decision was posted on the Centers for Medicare and Medicaid Services (CMS) website on January 12, and the coverage is scheduled to become effective for claims for services performed on or after February 27, 2006. The decision is posted at www.medicarenhic.com/cal_prov/updates.shtml.

"This decision will provide many more women access to this important tool when faced with a difficult treatment decision, including whether or not to undergo chemotherapy," said Kim Popovits, President and Chief Operating Officer of Genomic Health, Inc.

About Oncotype DX
Oncotype DX represents the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit. The test has been extensively evaluated in multiple independent studies involving more than 2,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine. For more information about Oncotype DX, please visit www.oncotypedx.com.

About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

GeneOhm Sciences Announces Agreement To Be Acquired by Becton Dickinson; Leader in Innovative Nucleic-Acid Based Diagnostic Solutions for Infection Prevention Joins World Leader in Clinical Diagnostic Products
San Diego , CA – January 10, 2006

GeneOhm Sciences, Inc., a privately held emerging leader in nucleic-acid based diagnostic solutions for the rapid detection of infectious microorganisms, announced today that it has reached an agreement to be acquired by BD (Becton, Dickinson and Company).

Jim Blair, Partner of Domain Associates, LLC and investor in GeneOhm Sciences since 2001 said, “We invested in GeneOhm to build a company with a leadership position in innovating new solutions for patient management through molecular diagnostics. The agreement to acquire GeneOhm by BD recognizes this accomplishment.” “GeneOhm Sciences has assembled a critical mass of people, products, technology and operations, including its facilities in Quebec City; with the support of BD, GeneOhm should continue in reaching its full potential,” comments André Archimbaud, Senior Vice President, Life Sciences Investments, for the Société Générale de Financement du Québec.

GeneOhm Sciences, formed in 2001 by Professor Jacqueline K. Barton of Caltech, develops and markets nucleic-acid based, molecular diagnostic tests for the rapid detection of bacterial microorganisms. It acquired Infectio Diagnostics, Inc., formed by Professor Michel Bergeron of Laval University , in 2004. One of GeneOhm's products, the IDI-MRSA™ assay, detects MRSA (Methicillin-resistant Staphylococcus aureus ) directly from clinical specimens in less than two hours—a time savings of almost 46 hours by comparison with established, culture-based methods.

MRSA is a deadly, antibiotic resistant pathogen known to cause healthcare-associated infections (HAIs). GeneOhm Sciences intends to develop a menu of rapid molecular diagnostic tests for organisms associated with HAIs and other infectious diseases as part of an initiative to transform patient care through rapid testing for infection prevention. HAIs represent a growing threat to patient safety in healthcare settings with approximately 6 million HAIs reported annually in the U.S., Canada, Japan and Europe. Active screening to identify patients colonized with MRSA is advocated by a number of thought leaders and leading institutions in the U.S. and Europe ; these institutions have adopted active screening programs to rapidly identify patients colonized with MRSA as a means of reducing HAIs.

GeneOhm Sciences launched the IDI- MRSA™ assay in November 2004, and the IDI-Strep B™ assay in December 2003. These assays were the first nucleic-acid based tests to be cleared by regulatory agencies such as FDA and Health Canada to replace conventional microbiological culture and directly test clinical specimens. Additional product launches are planned for 2006. The company had revenues in 2005 of approximately $5 million and quarterly growth of 48% through sales in the U.S., Canada and Europe.

Peter Klemm, CEO of GeneOhm Sciences, who will remain as President of BD-GeneOhm commented “BD recognizes the enormous potential of rapid, nucleic-acid based diagnostic solutions and that GeneOhm brings the innovative ingredients for BD to extend its leadership position to HAIs.”

Ron Lennox, General Partner CHL Medical Partners, LLC, said, “BD and GeneOhm are a perfect match; GeneOhm brings an entrepreneurial spirit and BD brings the strength of a company with more than 100 years of history.” Ben Schapiro, Partner, QuestMark Partners, LLC, said, “We are pleased for this outcome for all GeneOhm investors and employees; we see this merger as a further opportunity for the technology GeneOhm has developed to positively impact healthcare.” Rick Blume, Partner CB Health Ventures, LLC, stated, “We recognized GeneOhm's team as one that could develop technology and products for the right markets. BD is gaining an outstanding team and portfolio of technology; GeneOhm is gaining the support of a worldwide leader in diagnostics.”

About GeneOhm Sciences, Inc.
GeneOhm Sciences is a molecular diagnostic company with locations in San Diego , CA and Quebec City , Quebec , Canada . Its product portfolio includes two assays cleared by FDA and Health Canada for rapid detection of Group B Streptococcus (IDI-Strep B TM ) and Methicillin-Resistant Staphylococcus aureus (IDI-MRSA TM ) directly from clinical specimens. These are the first molecular diagnostic products to be cleared as meeting the specifications required to replace culture for microorganism detection. GeneOhm's product pipeline is based on the combination of the company's proprietary technology for nucleic acid detection and its broad molecular IP. To learn more about GeneOhm Sciences, please visit www.geneohm.com.

Contact:
Erik Holmlin, Ph.D.
Vice President, Business Development
GeneOhm Sciences
(858) 334-6330
eholmlin@geneohm.com

POINT Biomedical Submits New Drug Application (NDA) for CARDIOsphere® for the Assessment of Coronary Artery Disease
San Carlos , CA – January 9, 2006

POINT Biomedical Corp. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval to market CARDIOsphere (PB127) for the detection and localization of obstructive coronary artery disease. CARDIOsphere is a myocardial perfusion agent used with ultrasound imaging.

“The submission of this NDA is an important milestone for POINT”, said POINT CEO Dr. Jerry Griffin. “This is the first NDA submission for a myocardial perfusion imaging agent used with ultrasound. This NDA submission not only represents the dedicated efforts of our team but also that of an outstanding group of clinical investigators who were involved in the clinical development of CARDIOsphere. We are now looking forward to working with the FDA to ultimately be able to bring this procedure to patients as a non-invasive, non-radioactive means of assessing coronary artery disease.”

The NDA submission is based on the results of 11 clinical trials, involving more than 1300 patients and subjects including two multi-center Phase 3 clinical trials conducted in the United States. The Phase 3 trials were designed to evaluate the performance of CARDIOsphere for the assessment of myocardial perfusion using ultrasound imaging compared to radionuclide imaging, the current standard of care. If approved, CARDIOsphere will allow cardiologists to diagnose coronary artery disease in the office or hospital using standard ultrasound equipment and without the need for radioactive isotopes.

More than 13 million Americans suffer from coronary artery disease and an even larger number of individuals have risk factors or symptoms that make them potential candidates for coronary artery disease assessment by non-invasive means. Over 10 million non-invasive imaging procedures were performed to diagnose coronary artery disease in the U.S. last year.

About POINT Biomedical Corp.
POINT Biomedical Corp., based in San Carlos, CA is an emerging pharmaceutical company. The Company discovers and develops novel products for diagnostic, molecular imaging and drug delivery applications based on its patented biSphere technology. For additional information, please visit the POINT Biomedical website at www.pointbiomedical.com.

The matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of and market demand for products, among other matters, may differ significantly from the discussion of such matters in the forward-looking statements.